Physician profile
Christopher Harris
NPI 1295721355
$775.40
in general payments reported to CMS, 2019-2025
17 companies · $18.93 in 2025
The $18.93 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $636 · 2020: $60.08 · 2021: $20.63 · 2022: $12.57 · 2024: $27.63 · 2025: $18.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $46.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $46.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $99.02 | 2019 | |
| Amgen INC. | $88.23 | 2019 | |
| Rochester Medical Corporation | $75.90 | 2019-2021 | |
| Pfizer INC. | $62.12 | 2019 | |
| Neotract INC. | $60.08 | 2020 | |
| Endo Pharmaceuticals INC. | $53.31 | 2019 | |
| Dendreon Pharmaceuticals LLC | $52.40 | 2019 | |
| Ferring Pharmaceuticals INC. | $48.33 | 2019 | |
| Janssen Biotech, INC. | $42.26 | 2019 | |
| Abbvie INC. | $40.20 | 2022-2024 | |
| Boston Scientific Corporation | $35.02 | 2019 | |
| Coloplast Corp | $25.44 | 2019 | |
| Procept Biorobotics Corporation | $21.20 | 2019 | |
| Olympus America INC. | $18.93 | 2025 | Itind System |
| Sun Pharmaceutical Industries INC. | $18.74 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blue Earth Diagnostics | $17.40 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $16.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.